437 filings
10-K
2023 FY
FWBI
First Wave BioPharma Inc
Annual report
29 Mar 24
4:16pm
8-K
FWBI
First Wave BioPharma Inc
22 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
FWBI
First Wave BioPharma Inc
18 Mar 24
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
4:40pm
DEFA14A
FWBI
First Wave BioPharma Inc
18 Mar 24
Additional proxy soliciting materials
4:31pm
DEFA14A
FWBI
First Wave BioPharma Inc
14 Mar 24
Additional proxy soliciting materials
6:10am
8-K
8o4zrcm 3mmb
14 Mar 24
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
6:09am
8-K
9nmt1
5 Mar 24
First Wave BioPharma, Inc. to raise approximately $4.0 million of Gross Proceeds in Registered Direct Offering
5:26pm
424B5
68z20577m xk3c6lig48
4 Mar 24
Prospectus supplement for primary offering
5:29pm
424B3
sdn snhws8
18 Jan 24
Prospectus supplement
4:01pm
EFFECT
j8qcp9hl47vsrf66xc
18 Jan 24
Notice of effectiveness
12:15am
CORRESP
v90ad69kj6x6
16 Jan 24
Correspondence with SEC
12:00am
UPLOAD
jqxnyy4
12 Jan 24
Letter from SEC
12:00am
8-K
aul16n9e 7swriqp
4 Jan 24
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
8:22am
RW
x5oo70h6y xcktqlqc0h
28 Dec 23
Registration withdrawal request
12:21pm
8-K
2x2lu
27 Dec 23
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
5:23pm
8-K
8acoby6bs0ta49sgop2l
27 Dec 23
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
6:15am
8-K
etcpmrd2 wl
18 Dec 23
Other Events
7:00am